Sight Sciences (NASDAQ:SGHT) CTO Sells $27,638.60 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 3,695 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $7.48, for a total value of $27,638.60. Following the completion of the transaction, the chief technology officer directly owned 1,917,109 shares in the company, valued at $14,339,975.32. This trade represents a 0.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

David Badawi also recently made the following trade(s):

• On Monday, January 5th, David Badawi sold 3,051 shares of Sight Sciences stock. The shares were sold at an average price of $7.82, for a total value of $23,858.82.
• On Friday, January 2nd, David Badawi sold 2,914 shares of Sight Sciences stock. The stock was sold at an average price of $7.43, for a total transaction of $21,651.02.

Sight Sciences Stock Performance

NASDAQ SGHT traded down $0.24 on Tuesday, reaching $7.47. 197,717 shares of the stock were exchanged, compared to its average volume of 290,394. The company has a current ratio of 9.60, a quick ratio of 8.93 and a debt-to-equity ratio of 0.62. Sight Sciences, Inc. has a one year low of $2.03 and a one year high of $9.24. The firm has a market capitalization of $394.94 million, a PE ratio of -8.30 and a beta of 2.42. The company’s 50-day simple moving average is $7.52 and its two-hundred day simple moving average is $5.13.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings data on Wednesday, September 8th. The company reported ($0.81) earnings per share (EPS) for the quarter. The firm had revenue of $12.54 million during the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%. Analysts expect that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.

Institutional Trading of Sight Sciences

A number of large investors have recently added to or reduced their stakes in the company. Long Focus Capital Management LLC raised its holdings in shares of Sight Sciences by 1.3% during the 3rd quarter. Long Focus Capital Management LLC now owns 3,193,305 shares of the company’s stock worth $10,985,000 after acquiring an additional 41,797 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Sight Sciences by 145.2% in the third quarter. Millennium Management LLC now owns 133,846 shares of the company’s stock valued at $460,000 after purchasing an additional 79,265 shares in the last quarter. Alliancebernstein L.P. increased its position in Sight Sciences by 5.5% in the third quarter. Alliancebernstein L.P. now owns 34,380 shares of the company’s stock worth $118,000 after purchasing an additional 1,800 shares during the last quarter. BNP Paribas Financial Markets raised its stake in Sight Sciences by 99.8% during the third quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock valued at $26,000 after purchasing an additional 3,785 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Sight Sciences by 1.0% during the third quarter. Dimensional Fund Advisors LP now owns 303,634 shares of the company’s stock valued at $1,045,000 after purchasing an additional 3,051 shares in the last quarter. Institutional investors own 55.51% of the company’s stock.

Trending Headlines about Sight Sciences

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Piper Sandler upgraded Sight Sciences to Overweight (from Neutral), a buy-side analyst upgrade that can attract investor interest and buying momentum. Piper Sandler upgrade
• Neutral Sentiment: Despite recent sales, insiders still hold large positions — CEO Paul Badawi (~5.9M shares) and CTO David Badawi (~1.9M shares) retain substantial ownership, which can indicate alignment with long-term value even as they trim stakes. Insider ownership filing
• Negative Sentiment: Clustered insider selling by executives — CEO Paul Badawi, CTO David Badawi, CFO James Rodberg, EVP Brenton Taylor and insider Jeremy Hayden — over Jan. 2–6. Combined disclosed sales total roughly $0.48M across these transactions; each sale was a small percentage (<1%) of the seller’s holdings but the concentrated timing can create downward pressure on the stock. See CEO / executive filings. CEO sale filing CTO sale filing Other insider filings

Wall Street Analyst Weigh In

SGHT has been the topic of several research analyst reports. Morgan Stanley boosted their price objective on Sight Sciences from $6.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Citigroup boosted their price target on Sight Sciences from $5.50 to $9.10 and gave the stock a “neutral” rating in a report on Thursday, December 11th. Piper Sandler set a $9.00 price objective on shares of Sight Sciences in a report on Monday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sight Sciences in a research report on Monday, December 29th. Finally, UBS Group boosted their target price on shares of Sight Sciences from $7.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, December 23rd. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $8.30.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.